Lamivudine can be obtained as acicular crystals (form I, 0.2 hydrate) from water or methanol and as bipyramidal crystals (form II, nonsolvated) from many nonaqueous solvents. Lamivudine, used in the preparation of stable Lamivudine Form I, is amorphous Lamivudine, Lamivudine Form II. or a mixture of Form I or Form II. Stable Lamivudine Form I is prepared by crystallization of Lamivudine by dissolving in aqueous alcoholic solvent, preferably in 5-30% aqueous alcohol, more preferably in 15-20% aqueous alcohol. Lamivudine, a nucleoside reverse transcriptase inhibitor, is used in combination with other antiretroviral agents to treat human immunodeficiency virus Type 1 (HIV-1) View All Manufacturers & Suppliers of Lamivudine API with Drug Master Files (DMF), CEP/COS, Japanese DMFs, Written Confirmation (WC) details listed on PharmaCompass.com Lamivudine, used in the preparation of stable Lamivudine Form I, is amorphous Lamivudine, Lamivudine Form II. or a mixture of Form I or Form II. Stable Lamivudine Form I is prepared by crystallization of Lamivudine by dissolving in aqueous alcoholic solvent, preferably in 5-30% aqueous alcohol, more preferably in 15-20% aqueous alcohol. Lamivudine is known to exhibit polymorphism and the needle-shaped crystals are named as Form I and the bipyramidal crystals as Form II. The FT-Raman spectrum of lamivudine Form II and I shows. Abstract. The present study is focused on estimation of transition temperature and stability of various forms of lamivudine. The forms were recrystallized from variety of solvents and preliminarily identification on the basis of SEM revealed existence of three forms (Forms I, II, III). Hetero Drugs Limited offers a wide range of active pharmaceutical ingredients for regulated market which includes lamivudine form i & form ii. List of Drug Master Files (DMF) of Lamivudine Active Pharmaceutical Ingredient (API) submitted to the U.S. FDA. Original Data : FDA Website Lamivudine is indicated, in combination with zidovudine or other antiretroviral agents, in the treatment of HIV infection or AIDS when therapy is warranted based on clinical and/or immunological evidence of disease progression.